Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies

References

• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1–50
   Web of Science ®Google Scholar
• Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17:149–73; discussion 147
   Google Scholar
• Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of mania. World J Biol Psychiatry 2003;4:5–13
   PubMed Web of Science ®Google Scholar
• Vieta E. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry 2003;16:23–7
   Web of Science ®Google Scholar
• Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702–9
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000;57:841–9
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62–9
   PubMed Web of Science ®Google Scholar
• Keck Jr PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741–8
   PubMed Web of Science ®Google Scholar
• Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176–80
   Google Scholar
• Hirschfeld RM, Keck Jr PE, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057–65
   PubMed Web of Science ®Google Scholar
• Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003;182:141–7. Erratum in: Br J Psychiatry 2003;182: 369
   Google Scholar
• Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146–54
   PubMed Web of Science ®Google Scholar
• McIntyre RM, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12 week, double-blind, randomized, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005 [in press]
   Google Scholar
• Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111–21
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918–24
   PubMed Web of Science ®Google Scholar
• Cohen LS. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum, 1988
   Google Scholar
• Bowden CL, Davis J, Morris D, et al. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress Anxiety 1997;6:26–30
   PubMedGoogle Scholar
• Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452–54
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233–46
   Google Scholar
• Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30:95–105
   Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000:15:121–31
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549–57
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839–54
   Google Scholar
• Sajatovic M, Brescan DW, Perez DE, et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001;62:728–32
   PubMed Web of Science ®Google Scholar
• Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in patients with bipolar disorder and cocaine dependence. Bipolar Disord 2002;4:406–11
   PubMed Web of Science ®Google Scholar
• Post RM, Leverich GS, Altshuler LL, et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 2003;5:310–19
   PubMed Web of Science ®Google Scholar
• Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213–23
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Hennen J, Wilson M, et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol 2003;23:370–76
   PubMed Web of Science ®Google Scholar
• Grossman LS, Harrow M, Goldberg JF, et al. Outcome of schizoaffective disorder at two long-term follow-ups: comparisons with outcome of schizophrenia and affective disorders. Am J Psychiatry 1991;148:1359–65
   PubMed Web of Science ®Google Scholar
• Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003;23:S21–6
   PubMed Web of Science ®Google Scholar
• Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215–28
   PubMed Web of Science ®Google Scholar
• DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216–23
   PubMed Web of Science ®Google Scholar
• Ghaemi S, Goldberg J, Ko J, et al. Quetiapine treatment of rapid-cycling bipolar disorder: an open prospective study. Int J Neuropsychopharmacol 2002;5(Suppl 1):S110
   Google Scholar
• Vieta E, Parramon G, Padrell E, et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002;4:335–40
   PubMed Web of Science ®Google Scholar
• Vieta E, Carne X. The use of placebo in clinical trials on bipolar disorder: A new approach for an old debate. Psychother Psychosom 2005;74:10–6
   PubMed Web of Science ®Google Scholar
• Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599–606
   PubMed Web of Science ®Google Scholar